Abstract
Background
Detection of isolated tumour cells (ITC) in the blood or minimal deposits in distant organs such as bone marrow (BM) could be important to identify breast cancer patients at high risk of relapse or disease progression. PCR amplification of tissue or tumour selective mRNA is the most powerful analytical tool for detection of this micrometastasis. We have evaluated for the first time, the diagnostic accuracy of small breast epithelial mucin (SBEM) as a potential marker for BM micrometastasis in breast cancer.
Methods
A nested RT-PCR assay for detection of SBEM mRNA was compared with immunocytochemistry (ICC) with anticytokeratin AE1/AE3 antibody in paired samples obtained from the BM of breast cancer patients. Associations of SBEM mRNA detection in BM and clinical and pathological parameters were evaluated. SBEM mRNA status and time to breast cancer progression were analysed using Kaplan–Meyer curves.
Results
Fifty stages I–IV breast cancer female patients were prospectively included in our study. SBEM specific transcript was found in BM in 26% of the patients. Detection rate was similar to the percentage of patients with ITCs detected using ICC (24%). SBEM mRNA in BM aspirates were significantly associated with presence of clinically active disease, including locally advanced and metastatic patients (47%, P = 0.021) and tumours with positive hormonal receptors (36.7%, P = 0.035). In addition association with Her2/neu over-expression (44.4%, P = 0.051) and low proliferating tumours (36%, P = 0.067) were close to significant levels. When we analysed time to breast cancer progression adjusting for grade or hormone receptor status, presence of SBEM mRNA in BM defines distinct prognostic groups.
Conclusions
SBEM might represent a suitable marker for molecular detection of ITCs in BM in breast cancer patients. Analysis of prognostic value for SBEM mRNA-based assay should take into account the heterogeneity and different molecular subtypes of breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ITC:
-
Isolated tumour cells
- ICC:
-
Immunocytochemistry
- CK:
-
Cytokeratin
- RT-PCR:
-
Reverse-transcriptase polymerase-chain reaction
- SBEM:
-
Small breast epithelial mucin
- BM:
-
Bone marrow
- TTP:
-
Time to breast cancer progression
- HR:
-
Hormonal receptors
References
AceView: a comprehensive cDNA-supported gene and transcripts annotation. http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?exdb=AceView&db=36a&term=SBEM&submit=Go
Allinen M, Beroukhim R, Cai L et al (2004) Molecular characterization of the tumour microenvironment in breast cancer. Cancer Cell 6:17–32. doi:10.1016/j.ccr.2004.06.010
Ayerbes MV, Díaz-Prado S, Ayude D et al (2008) In silico and in vitro analysis of small breast epithelial mucin as a marker for bone marrow micrometastasis in breast cancer. Adv Exp Med Biol 617:331–339. doi:10.1007/978-0-387-69080-3_31
Benoy IH, Elst H, Van der Auwera I et al (2004) Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Br J Cancer 91:1813–1820. doi:10.1038/sj.bjc.6602189
Bidard FC, Vincent-Salomon A, Gomme S et al (2008a) Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 14:3306–3311. doi:10.1158/1078-0432.CCR-07-4749
Bidard FC, Vincent-Salomon A, Sigal-Zafrani B et al (2008b) Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 19:496–500. doi:10.1093/annonc/mdm507
Borgen E, Naume B, Nesland et al (1999) Standardisation of the immunocytochemical detection of cancer cells inbone marrow and blood. I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1:377–388. doi:10.1080/0032472031000141283
Braun S, Naume B (2005) Circulating and disseminated tumour cells. Review Article. J Clin Oncol 23:1623–1626. doi:10.1200/JCO.2005.10.073
Braun S, Pantel K, Müller P et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med 342:525–533. doi:10.1056/NEJM200002243420801
Braun S, Vogl F, Naume B et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802. doi:10.1056/NEJMoa050434
Brown NM, Stenzel TT, Friedman PN, Henslee J, Huper G, Marks JR (2006) Evaluation of expression based markers for the detection of breast cancer cells. Breast Cancer Res Treat 97:41–47. doi:10.1007/s10549-005-9085-8
Choesmel V, Pierga JY, Nos C, Vincent-Salomon A, Sigal-Zafrani B, Thiery JP, Blin N (2004) Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance. Breast Cancer Res 6:R556–R569. doi:10.1186/bcr898
Colpitts TL, Billing P, Granados E et al (2002) Identification and immunohistochemical characterization of a mucin-like glycoprotein expressed in early stage breast carcinoma. Tumour Biol 23:263–278. doi:10.1159/000068566
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592. doi:10.1093/annonc/mdl498
Gangnus R, Langer S, Breit E, Pantel K, Speicher MR (2004) Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res 10:3457–3464. doi:10.1158/1078-0432.CCR-03-0818
Houghton RL, Dillon DC, Molesh DA et al (2001) Transcriptional complementarity in breast cancer: application to detection of circulating tumour cells. Mol Diagn 6:79–91. doi:10.2165/00066982-200106020-00003
Ignatiadis M, Xenidis N, Perraki M et al (2007) Different prognostic value of cytokeratin-19 mRNA positive circulating tumour cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25:5194–5202. doi:10.1200/JCO.2007.11.7762
Janni W, Gastroph S, Hepp F et al (2000) Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer 88:2252–2259. doi:10.1002/(SICI)1097-0142(20000515)88:10<2252::AID-CNCR8>3.0.CO;2-Q
Klein CA, Blankenstein TJF, Schmidt-Kittler O et al (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360:683–689. doi:10.1016/S0140-6736(02)09838-0
Kruger WH, Jung R, Detlefsen B et al (2001) Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells. Med Oncol 18:33–38. doi:10.1385/MO:18:1:33
Lacroix M (2006) Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13:1033–1067. doi:10.1677/ERC-06-0001
Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83:249–289. doi:10.1023/B:BREA.0000014042.54925.cc
Lambrechts AC, Bosma AJ, Klaver SG, Top B, Perebolte L, van’t Veer LJ, Rodenhuis S (1999) Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Res Treat 56:219–231. doi:10.1023/A:1006261731125
Ma X-J, Salunga R, Tuggle JT et al (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100:5974–5979. doi:10.1073/pnas.0931261100
Miksicek RJ, Myal Y, Watson PH, Walker C, Murphy LC, Leygue E (2002) Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumour human mammary epithelium. Cancer Res 62:2736–2740
Muller V, Stahmann N, Riethdorf S et al (2005) Circulating tumour cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11:3678–3685. doi:10.1158/1078-0432.CCR-04-2469
Naume B, Zhao X, Synnestvedt M et al (2007) Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 1:160–171. doi:10.1016/j.molonc.2007.03.004
Pantel K, Alix-Panabieres C (2007) The clinical significance of circulating tumour cells. Nat Clin Pract Oncol 4:62–63. doi:10.1038/ncponc0737
Pantel K, Schlimok G, Braun S et al (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419–1424. doi:10.1093/jnci/85.17.1419
Pantel K, Schlimok G, Angstwurm M et al (1994) Methodological analysis of immunocytochemical screening for disseminated epithelial tumour cells in bone marrow. J Hematother 3:165–173
Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M (2005) Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 92:906–912. doi:10.1038/sj.bjc.6602418
Rozen S, Skaletsky HJ (2000) Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics methods and protocols: methods in molecular biology. Humana Press, Totowa, pp 365–386
Schindlbeck C, Kampik T, Janni W et al (2005) Prognostic relevance of disseminated tumour cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res 7:R1174–R1185. doi:10.1186/bcr1360
Schoenfeld A, Kruger KH, Gomm J et al (1997) The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 33:854–861. doi:10.1016/S0959-8049(97)00014-2
Skliris GP, Hube′ F, Gheorghiu I et al (2008) Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology 52:355–369. doi:10.1111/j.1365-2559.2007.02955.x
Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC (1999) Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol 17:870–879
Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JWW (2008) An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107:309–330. doi:10.1007/s10549-007-9556-1
Verdecchia A, Francisci S, Brenner H et al (2007) Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784–796. doi:10.1016/S1470-2045(07)70246-2
Watson MA, Ylagan LA, Trinkaus KM et al (2007) Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumour relapse in breast cancer patients. Clin Cancer Res 13:5001–5009. doi:10.1158/1078-0432.CCR-07-0024
Wiedswang G, Borgen E, Karesen R et al (2003) Detection of isolated tumour cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21:3469–3478. doi:10.1200/JCO.2003.02.009
Willipinski-Stapelfeldt B, Riethdorf S, Assmann V et al (2005) Changes in cytoskeletal protein composition indicative of an epithelial–mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11:8006–8014. doi:10.1158/1078-0432.CCR-05-0632
Woelfle U, Cloos J, Sauter G et al (2003) Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 63:5679–5684
Acknowledgments
This study was supported by grant 2000-5435256011 from Universidade da Coruña. S. Díaz-Prado is supported by an Isidro Parga Pondal research contract by Xunta de Galicia. The authors wish to thank S. Pértega Díaz for excellent statistical assistance. Cancer research in our laboratory is supported by the “Fundación Juan Canalejo-Marítimo de Oza.”
Conflict of interest statement
None declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Valladares-Ayerbes, M., Iglesias-Díaz, P., Díaz-Prado, S. et al. Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study. J Cancer Res Clin Oncol 135, 1185–1195 (2009). https://doi.org/10.1007/s00432-009-0559-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0559-7